Tilray Medical Welcomes Government of Luxembourg Delegation Visit to European Campus in Portugal
22 Juni 2022 - 1:00PM
Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX:
TLRY), a leading global cannabis-lifestyle and consumer packaged
goods company inspiring and empowering the worldwide community to
live their very best life, welcomes the Luxembourg Ministry of
Health Delegation to the Company’s European campus and facility
located in Cantanhede, Portugal. Tilray’s EU-GMP-certified medical
cannabis cultivation and manufacturing facility in Portugal
provides patients in Luxembourg and across Europe, where permitted
by law, with safe and reliable access to high-quality medical
cannabis.
The visit was organized to give the Luxembourg
Delegation a firsthand view of Tilray’s EU-GMP operations in
Portugal, the premiere medical cannabis site in Europe. The
delegation included:
- Paulette Lenert, Deputy Prime
Minister and Minister of Health of Luxembourg
- H. E. Conrad Bruch, Ambassador of
Luxembourg to Portugal
- Alain Origer, National Drugs
Coordinator
- Laura Valli, International Affairs
Coordinator
- Bob Lessel, Social Health
Department
- Sven Back, Department of narcotics
and medicinal cannabis
Sascha Mielcarek, Tilray’s Managing Director in
Europe, said, “We are honored to host the Luxembourg Ministry of
Health Delegation at our state-of-the-art cannabis facility in
Cantanhede, Portugal. Demand for cannabis legalization in Europe is
growing rapidly and we are incredibly proud to service the patients
in Luxembourg and around the world with the high-quality medical
cannabis products they rely on and in the formats they prefer.”
Tilray has a pioneering track record as a
company committed to producing the highest-quality cannabis
products available to consumers and patients in need around the
world and was the first to successfully export medical cannabis
from North America and import medical cannabis products into the EU
in 2016.
About Tilray
Medical Tilray Medical is dedicated to transforming
lives and fostering dignity for patients in need through safe and
reliable access to a global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew
from being one of the first companies to become an approved
licensed producer of medical cannabis in Canada to building the
first GMP-certified cannabis production facilities in Europe, first
in Portugal and later in Germany. Today, Tilray Medical is one of
the biggest suppliers of medical cannabis brands to patients,
physicians, hospitals, pharmacies, researchers, and governments, in
20 countries and across five continents.
For more information on Tilray Medical, visit
Tilray Medical Canada, Tilray Medical Australia, Tilray Medical
Australia-New Zealand, Tilray Medical Europe
About Tilray BrandsTilray
Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global
cannabis-lifestyle and consumer packaged goods company with
operations in Canada, the United States, Europe, Australia, and
Latin America that is changing people's lives for the better – one
person at a time. Tilray Brands delivers on this mission by
inspiring and empowering the worldwide community to live their very
best life and providing access to products that meet the needs of
their mind, body, and soul while invoking wellbeing. Patients and
consumers trust Tilray Brands to deliver a cultivated experience
and health and wellbeing through high-quality, differentiated
brands and innovative products. A pioneer in cannabis research,
cultivation, and distribution, Tilray’s unprecedented production
platform supports over 20 brands in over 20 countries, including
comprehensive cannabis offerings, hemp-based foods, and craft
beverages. For more information on how we open a world of
wellbeing, visit www.Tilray.com.
Forward-Looking
StatementsCertain statements in this communication that
are not historical facts constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: expectations regarding
the performance and scale of the Company, including Tilray Medical;
and the Company’s ability to expand its offering to patients
worldwide, including via Tilray Medical. Many factors could cause
actual results, performance or achievement to be materially
different from any forward-looking statements, and other risks and
uncertainties not presently known to the Company or that the
Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking
statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual
information form of Tilray and the Annual Report on Form 10-K (and
other periodic reports filed with the SEC) of Tilray made with the
SEC and available on EDGAR. The forward-looking statements included
in this communication are made as of the date of this communication
and the Company does not undertake any obligation to publicly
update such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities laws.
ContactsTilray GlobalBerrin
Noorata news@tilray.com
InvestorsRaphael
Gross203-682-8253Raphael.Gross@icrinc.co
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/56cca4b1-684d-402b-ab7b-1c3f2ca19509
Tilray Brands (TSX:TLRY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Tilray Brands (TSX:TLRY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024